Please login to the form below

Not currently logged in
Email:
Password:

alpharadin

This page shows the latest alpharadin news and features for those working in and with pharma, biotech and healthcare.

FDA clears Bayer/ Algeta's prostate cancer radiotherapy

FDA clears Bayer/ Algeta's prostate cancer radiotherapy

Analysts have predicted that Xofigo (formerly known as Alpharadin) could achieve sales of $650m within three years of launch and more than $1bn a year at its peak if follow-up

Latest news

  • Bayer pins hopes on five potential blockbusters Bayer pins hopes on five potential blockbusters

    Bayer pins hopes on five potential blockbusters. Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of 5.5bn by 2015. ... The German company's expectations are high for it yet to be approved riociguat and alpharadin (radium-223

  • FDA fast-tracks Bayer's prostate cancer radiotherapy FDA fast-tracks Bayer's prostate cancer radiotherapy

    FDA fast-tracks Bayer's prostate cancer radiotherapy. Priority review for radium-223 dichloride, formerly called Alpharadin. ... The FDA granted priority review status to radium-223 dichloride - formerly called Alpharadin - for the treatment of

  • New hope for castration-resistant prostate cancer New hope for castration-resistant prostate cancer

    Another bone-targeting agent in phase III trials of use in patients with CRPC and bone metastases is radium-223 chloride (Alpharadin; Algeta, Bayer Healthcare), a first-in-class, highly targeted

  • Developing drugs to conquer cancer Developing drugs to conquer cancer

    Bayer HealthCare discussed phase III results concerning regorafenib in gastrointestinal stromal tumour (GIST) and in colorectal cancer, as well as the final overall survival analysis of radium-223 (Alpharadin) data in

  • Bayer raises 2012 forecasts on increasing revenues Bayer raises 2012 forecasts on increasing revenues

    Bayer has previously highlighted four potential blockbusters in its late-stage pipeline, including Xarelto, Eylea (aflibercept) for wet age-related macular degeneration (AMD) and two cancer drugs, namely alpharadin for bone

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics